Edition:
United States

Loxo Oncology Inc (LOXO.OQ)

LOXO.OQ on NASDAQ Stock Exchange Global Market

74.19USD
16 Aug 2017
Change (% chg)

$0.67 (+0.91%)
Prev Close
$73.52
Open
$73.67
Day's High
$76.68
Day's Low
$73.67
Volume
90,975
Avg. Vol
124,172
52-wk High
$83.10
52-wk Low
$17.14

Latest Key Developments (Source: Significant Developments)

Loxo Oncology posts Q3 loss per share $1.14
Tuesday, 8 Aug 2017 06:45am EDT 

Aug 8 (Reuters) - Loxo Oncology Inc :Loxo Oncology announces second quarter 2017 financial results.Loxo Oncology Inc qtrly loss per share $1.14.Q2 earnings per share view $-0.98 -- Thomson Reuters I/B/E/S.  Full Article

Loxo Oncology acquires BTK inhibitor program
Monday, 31 Jul 2017 06:45am EDT 

July 31 (Reuters) - Loxo Oncology Inc :Loxo Oncology announces acquisition of highly selective, reversible BTK inhibitor program.Loxo Oncology Inc - ‍entered into a definitive agreement to purchase Bruton's Tyrosine Kinase inhibitor program from RedX Pharma PLC​.Loxo Oncology Inc - ‍under terms of agreement, Loxo Oncology has made a $40 million payment to RedX Pharma PLC for full acquisition of BTK discovery program​.Loxo Oncology Inc - ‍lead candidate from this program is expected to enter clinical development in 2018​.Loxo Oncology Inc - Loxo Oncology is not subject to milestone or royalty obligations.  Full Article

Redx Pharma says disposal of BTK inhibitor drug development program
Monday, 31 Jul 2017 02:00am EDT 

July 31 (Reuters) - Redx Pharma Plc ::DISPOSAL OF BTK INHIBITOR DRUG DEVELOPMENT PROGRAM.SAYS ‍JOINT ADMINISTRATORS OF CO, UNIT ENTERED INTO AN UNCONDITIONAL AGREEMENT FOR DISPOSAL TO LOXO ONCOLOGY INC.​.SAYS DISPOSAL ‍FOR SUM OF US$40 MILLION​.  Full Article

Loxo Oncology prices follow-on offering of common stock
Wednesday, 14 Jun 2017 09:20pm EDT 

June 14 (Reuters) - Loxo Oncology Inc ::Loxo Oncology prices follow-on offering of common stock.Says public offering of 3.15 million common shares priced at $72.00per share.  Full Article

Loxo Oncology announces proposed public offering of common stock
Tuesday, 13 Jun 2017 04:02pm EDT 

June 13 (Reuters) - Loxo Oncology Inc : :Loxo Oncology announces proposed public offering of common stock.Loxo Oncology- to use proceeds for early commercialization activities for larotrectinib, research and development activities, including those related to Loxo-195, Loxo-292.  Full Article

Loxo Oncology announces FDA clearance of investigational new drug application for next-generation trk inhibitor
Tuesday, 30 May 2017 06:45am EDT 

May 30 (Reuters) - Loxo Oncology Inc :Loxo Oncology announces fda clearance of investigational new drug (ind) application for next-generation trk inhibitor, loxo-195.Loxo-195 will initially be studied in a multi-center phase 1/2 trial.Loxo Oncology inc says primary objective of trial is to determine maximum tolerated dose or recommended dose for further study.Trial will include a dose escalation phase and dose expansion phase.Loxo Oncology - loxo-195 will be developed as sequential treatment, to follow larotrectinib/another trk inhibitor, to extend time for trk inhibition benefit.  Full Article

Loxo Oncology announces FDA orphan drug designation granted to larotrectinib
Friday, 12 May 2017 06:45am EDT 

May 12 (Reuters) - Loxo Oncology Inc : :Loxo Oncology announces FDA orphan drug designation granted to larotrectinib for the treatment of solid tumors with ntrk-fusion proteins.  Full Article

Loxo Oncology announces enrollment of first patient in phase 1 clinical trial of loxo-292
Wednesday, 10 May 2017 06:45am EDT 

May 10 (Reuters) - Loxo Oncology Inc : :Loxo Oncology announces enrollment of first patient in phase 1 clinical trial for highly selective ret inhibitor, loxo-292.  Full Article

Loxo Oncology qtrly loss per share $0.96
Tuesday, 9 May 2017 06:45am EDT 

May 9 (Reuters) - Loxo Oncology Inc :Loxo oncology announces first quarter 2017 financial results.Qtrly loss per share $0.96.Q1 earnings per share view $-0.90 -- Thomson Reuters I/B/E/S.  Full Article

Loxo Oncology reports completion of clinical trial enrollment for larotrectinib NDA primary efficacy analysis
Tuesday, 21 Feb 2017 06:45am EST 

Loxo Oncology Inc : Loxo Oncology announces completion of clinical trial enrollment for larotrectinib nda primary efficacy analysis . Loxo Oncology Inc - company expects to report top-line data for NDA dataset in second half of 2017 .Loxo Oncology- expects to submit a new drug application in late 2017 or early 2018, and European marketing authorisation application in 2018.  Full Article

BRIEF-Loxo Oncology posts Q3 loss per share $1.14

* Loxo Oncology announces second quarter 2017 financial results